CR20200061A - Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de células b grandes difusas (dlbcl) - Google Patents
Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de células b grandes difusas (dlbcl)Info
- Publication number
- CR20200061A CR20200061A CR20200061A CR20200061A CR20200061A CR 20200061 A CR20200061 A CR 20200061A CR 20200061 A CR20200061 A CR 20200061A CR 20200061 A CR20200061 A CR 20200061A CR 20200061 A CR20200061 A CR 20200061A
- Authority
- CR
- Costa Rica
- Prior art keywords
- dlbcl
- patients
- new
- obinutuzumab
- patient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a obinutuzumab (o sus equivalentes funcionales) para el uso en el tratamiento de un paciente con DLBCL definido por biomarcador particular y un subgrupo de pacientes DLBCL novedoso, respectivamente. La presente invención se refiere además a un método para tratar DLBCL con obinutuzumab (o sus equivalentes funcionales) en un paciente en necesidad del mismo, en donde el paciente es un paciente con DLBCL definido por biomarcador particular o que pertenece a un subgrupo de pacientes DLBCL definido por biomarcador novedoso. La presente invención se refiere además al uso de obinutuzumab (o sus equivalentes funcionales) para la preparación de una composición farmacéutica para el tratamiento de DLBCL en el subgrupo de pacientes con DLBCL definido por biomarcador particular/paciente con DLBCL novedoso. La presente invención se refiere además a un método para identificar un subgrupo de pacientes con DLBCL particular/paciente con DLBCL novedoso y un método para diagnosticar una forma novedosa de DLBCL y un subgrupo de pacientes con DLBCL particular/paciente con DLBCL novedosos, respectivamente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762542489P | 2017-08-08 | 2017-08-08 | |
| PCT/EP2018/071462 WO2019030260A1 (en) | 2017-08-08 | 2018-08-08 | OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200061A true CR20200061A (es) | 2020-05-23 |
Family
ID=63209389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200061A CR20200061A (es) | 2017-08-08 | 2018-08-08 | Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de células b grandes difusas (dlbcl) |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11597772B2 (es) |
| EP (1) | EP3665196B1 (es) |
| JP (2) | JP7418322B2 (es) |
| KR (1) | KR102799421B1 (es) |
| CN (2) | CN119798437A (es) |
| AU (1) | AU2018314765C1 (es) |
| CA (1) | CA3071618A1 (es) |
| CR (1) | CR20200061A (es) |
| ES (1) | ES2933256T3 (es) |
| IL (1) | IL272418B2 (es) |
| MA (1) | MA49830A (es) |
| MX (1) | MX2020001493A (es) |
| MY (1) | MY202382A (es) |
| PE (1) | PE20200738A1 (es) |
| PL (1) | PL3665196T3 (es) |
| SG (1) | SG11202000985XA (es) |
| TW (2) | TWI909088B (es) |
| UA (1) | UA126204C2 (es) |
| WO (1) | WO2019030260A1 (es) |
| ZA (1) | ZA202000680B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| AU2018314765C1 (en) | 2017-08-08 | 2025-11-20 | Bruker Spatial Biology, Inc. | Obinutuzumab treatment of a DLBCL patient subgroup |
| GB2596411B (en) * | 2018-10-29 | 2023-09-20 | Tigatx Inc | Compositions and methods comprising IgA antibody constructs |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| US20240207281A1 (en) * | 2021-04-21 | 2024-06-27 | Celgene Corporation | Methods of treating b-cell lymphoma using combination therapy |
| CN117241802A (zh) * | 2021-04-21 | 2023-12-15 | 新基公司 | 使用2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮治疗非霍奇金淋巴瘤的方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2957177B2 (ja) | 1986-03-20 | 1999-10-04 | 日本電気株式会社 | マイクロコンピユータ |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| ATE230277T1 (de) | 1997-06-13 | 2003-01-15 | Genentech Inc | Stabilisierte antikörperformulierung |
| HUE038955T2 (hu) | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval |
| GB0718684D0 (en) * | 2007-09-24 | 2007-10-31 | Roche Products Ltd | Treatment method |
| US20130195843A1 (en) * | 2010-06-23 | 2013-08-01 | British Columbia Cancer Agency Branch | Biomarkers for Non-Hodgkin Lymphomas and Uses Thereof |
| ES2738289T3 (es) * | 2013-11-06 | 2020-01-21 | Hospital Clinic Barcelona | Procedimiento para el subtipado de tipos de linfoma por medio de perfiles de expresión |
| DE102013222576A1 (de) | 2013-11-06 | 2015-05-07 | BSH Bosch und Siemens Hausgeräte GmbH | Haushaltsgerät |
| CA2926893C (en) | 2013-11-07 | 2022-04-12 | F. Hoffmann-La Roche Ag | Combination therapy of an anti cd20 antibody with a btk inhibitor |
| EP3122900A1 (en) * | 2014-03-24 | 2017-02-01 | F. Hoffmann-La Roche AG | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
| ES2949173T3 (es) * | 2014-09-15 | 2023-09-26 | Hoffmann La Roche | Formulaciones de anticuerpo |
| CA2979671C (en) * | 2014-09-23 | 2020-03-10 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates |
| BR112017026027A2 (pt) * | 2015-06-08 | 2018-08-14 | Debiopharm Int Sa | combinações de imunoconjugado anti-cd37 e anticorpo anti-cd20 |
| CN107847592B (zh) | 2015-06-24 | 2022-01-21 | 豪夫迈·罗氏有限公司 | 用于在淋巴瘤或白血病中诱导淋巴细胞增多的针对人csf-1r的抗体 |
| EP3178848A1 (en) * | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
| IL313608A (en) * | 2015-12-09 | 2024-08-01 | Hoffmann La Roche | Antibody against CD20 type II to reduce the formation of antibodies against drugs |
| AU2018314765C1 (en) * | 2017-08-08 | 2025-11-20 | Bruker Spatial Biology, Inc. | Obinutuzumab treatment of a DLBCL patient subgroup |
-
2018
- 2018-08-08 AU AU2018314765A patent/AU2018314765C1/en active Active
- 2018-08-08 CA CA3071618A patent/CA3071618A1/en active Pending
- 2018-08-08 PE PE2020000199A patent/PE20200738A1/es unknown
- 2018-08-08 CN CN202411647297.0A patent/CN119798437A/zh active Pending
- 2018-08-08 MX MX2020001493A patent/MX2020001493A/es unknown
- 2018-08-08 UA UAA202001356A patent/UA126204C2/uk unknown
- 2018-08-08 MY MYPI2020000328A patent/MY202382A/en unknown
- 2018-08-08 TW TW111133199A patent/TWI909088B/zh active
- 2018-08-08 SG SG11202000985XA patent/SG11202000985XA/en unknown
- 2018-08-08 CN CN201880051243.4A patent/CN111032692A/zh active Pending
- 2018-08-08 ES ES18755421T patent/ES2933256T3/es active Active
- 2018-08-08 KR KR1020207006102A patent/KR102799421B1/ko active Active
- 2018-08-08 CR CR20200061A patent/CR20200061A/es unknown
- 2018-08-08 WO PCT/EP2018/071462 patent/WO2019030260A1/en not_active Ceased
- 2018-08-08 JP JP2020505912A patent/JP7418322B2/ja active Active
- 2018-08-08 EP EP18755421.7A patent/EP3665196B1/en active Active
- 2018-08-08 MA MA049830A patent/MA49830A/fr unknown
- 2018-08-08 TW TW107127631A patent/TWI772488B/zh active
- 2018-08-08 IL IL272418A patent/IL272418B2/en unknown
- 2018-08-08 PL PL18755421.7T patent/PL3665196T3/pl unknown
-
2020
- 2020-01-31 ZA ZA2020/00680A patent/ZA202000680B/en unknown
- 2020-02-06 US US16/784,021 patent/US11597772B2/en active Active
-
2023
- 2023-02-02 US US18/163,810 patent/US20230348611A1/en active Pending
- 2023-08-24 JP JP2023136335A patent/JP2023179425A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006238A (es) | Metodos para tratamiento que usan terapia celular adoptiva. | |
| MX2020005165A (es) | Biogenesis de miarn en exosomas para diagnostico y terapia. | |
| MX2021006980A (es) | Anticuerpos anti-il-27 y usos de estos. | |
| MX2017001302A (es) | Biomarcadores para predecir la respuesta del dlbcl al tratamiento con un inhibidor de la btk. | |
| MX2020001493A (es) | Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de celulas b grandes difusas (dlbcl). | |
| MX2017006268A (es) | Administracion intranasal. | |
| UY35013A (es) | Composiciones farmacéuticas que contienen un antagonista de il-4r y sus usos | |
| MX2018009738A (es) | Anticuerpos monoclonales de proteína ns1 anti-virus del dengue. | |
| BR112018006045A2 (pt) | análise de marcador de massa para células raras e moléculas isentas de células | |
| MX2015013948A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| AR088083A1 (es) | USO DE ANTICUERPOS DE UNION A IL-1b | |
| AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
| BR112015019873A2 (pt) | inibidores macrocíclicos da lrrk2 cinase | |
| AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
| CL2020001936A1 (es) | Métodos para el tratamiento de la atrofía muscular espinal. | |
| CO2020008863A2 (es) | Biomarcadores de tolerancia inmunitaria inducida por metotrexato | |
| MX360236B (es) | Uso de marcadores en el diagnostico y tratamiento de cancer de prostata. | |
| MX2020009879A (es) | Anticuerpos anti-il-27 y sus usos. | |
| BR112016023607A2 (pt) | uso médico de compostos de artemisinina e agonistas de gefirina | |
| BR112021015222A2 (pt) | Métodos, sistemas e kits para tratamento de doença inflamatória de alvejamento de il18r1 | |
| MX2019003619A (es) | Formulaciones de bromocriptina. | |
| MX2022003719A (es) | Anticuerpos anti-il-27 y sus usos. | |
| MX381544B (es) | Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto. | |
| EA201591773A1 (ru) | Макроциклические ингибиторы rip2-киназы | |
| AR087363A1 (es) | Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres |